<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topical clonidine for neuropathic pain in adults - Serednicki, WT - 2022 | Cochrane Library</title> <meta content="Topical clonidine for neuropathic pain in adults - Serednicki, WT - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010967.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topical clonidine for neuropathic pain in adults - Serednicki, WT - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010967.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010967.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Topical clonidine for neuropathic pain in adults" name="citation_title"/> <meta content="Wojciech T Serednicki" name="citation_author"/> <meta content="Anna Wrzosek" name="citation_author"/> <meta content="awrzosek@su.krakow.pl" name="citation_author_email"/> <meta content="Jaroslaw Woron" name="citation_author"/> <meta content="Jaroslaw Garlicki" name="citation_author"/> <meta content="Jan Dobrogowski" name="citation_author"/> <meta content="Joanna Jakowicka-Wordliczek" name="citation_author"/> <meta content="Jerzy Wordliczek" name="citation_author"/> <meta content="Renata Zajaczkowska" name="citation_author"/> <meta content="Jagiellonian University Collegium Medicum" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD010967.pub3" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/05/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010967.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010967.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010967.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Analgesics [therapeutic use]; *Chronic Pain [drug therapy]; Clonidine [adverse effects]; *Diabetic Neuropathies [drug therapy]; *Neuralgia [drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010967.pub3&amp;doi=10.1002/14651858.CD010967.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010967\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010967\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","th","ms","ja","hr","fa","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010967.pub3",title:"Topical clonidine for neuropathic pain in adults",firstPublishedDate:"May 19, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010967.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010967.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010967.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010967.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010967.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010967.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010967.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010967.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010967.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010967.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6355 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010967.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0094"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-sec-0088"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/appendices#CD010967-sec-0106"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/supinfo/CD010967StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/supinfo/CD010967StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topical clonidine for neuropathic pain in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0004">Wojciech T Serednicki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Anna Wrzosek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0006">Jaroslaw Woron</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0007">Jaroslaw Garlicki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0008">Jan Dobrogowski</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0009">Joanna Jakowicka-Wordliczek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0010">Jerzy Wordliczek</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information#CD010967-cr-0011">Renata Zajaczkowska</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information/en#CD010967-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 May 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010967.pub3">https://doi.org/10.1002/14651858.CD010967.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010967-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010967-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010967-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010967-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010967-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD010967-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010967-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010967-abs-0001" lang="en"> <section id="CD010967-sec-0001"> <h3 class="title" id="CD010967-sec-0001">Background</h3> <p>Clonidine is a presynaptic alpha‐2‐adrenergic receptor agonist that has been used for many years to treat hypertension and other conditions, including chronic pain. Adverse events associated with systemic use of the drug have limited its application. Topical use of drugs has been gaining interest since the beginning of the century, as it may limit adverse events without loss of analgesic efficacy. Topical clonidine (TC) formulations have been investigated for almost 20 years in clinical trials. This is an update of the original Cochrane Review published in Issue 8, 2015. </p> </section> <section id="CD010967-sec-0002"> <h3 class="title" id="CD010967-sec-0002">Objectives</h3> <p>The objective of this review was to assess the analgesic efficacy and safety of TC compared with placebo or other drugs in adults aged 18 years or above with chronic neuropathic pain. </p> </section> <section id="CD010967-sec-0003"> <h3 class="title" id="CD010967-sec-0003">Search methods</h3> <p>For this update we searched the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid), and Embase (Ovid) databases, and reference lists of retrieved papers and trial registries. We also contacted experts in the field. The most recent search was performed on 27 October 2021. </p> </section> <section id="CD010967-sec-0004"> <h3 class="title" id="CD010967-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind studies of at least two weeks' duration comparing TC versus placebo or other active treatment in adults with chronic neuropathic pain. </p> </section> <section id="CD010967-sec-0005"> <h3 class="title" id="CD010967-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened references for eligibility, extracted data, and assessed risk of bias. Any discrepancies were resolved by discussion or by consulting a third review author if necessary. Where required, we contacted trial authors to request additional information. </p> <p>We presented pooled estimates for dichotomous outcomes as risk ratios (RRs) with 95% confidence intervals (CIs), and continuous outcomes as mean differences (MDs) with P values. We used Review Manager Web software to perform the meta‐analyses. We used a fixed‐effect model if we considered heterogeneity as not important; otherwise, we used a random‐effects model.  </p> <p>The review primary outcomes were: participant‐reported pain relief of 50% or greater; participant‐reported pain relief of 30% or greater; much or very much improved on Patient Global Impression of Change scale (PGIC); and very much improved on PGIC. Secondary outcomes included withdrawals due to adverse events; participants experiencing at least one adverse event; and withdrawals due to lack of efficacy. All outcomes were measured at the longest follow‐up period. </p> <p>We assessed the certainty of evidence using GRADE and created two summary of findings tables. </p> </section> <section id="CD010967-sec-0006"> <h3 class="title" id="CD010967-sec-0006">Main results</h3> <p>We included four studies in the review (two new in this update), with a total of 743 participants with painful diabetic neuropathy (PDN). TC (0.1% or 0.2%) was applied in gel form to the painful area two to three times daily. The double‐blind treatment phase of three studies lasted 8 weeks to 85 days and compared TC versus placebo. In the fourth study, the double‐blind treatment phase lasted 12 weeks and compared TC versus topical capsaicin. We assessed the studies as at unclear or high risk of bias for most domains; all studies were at unclear risk of bias for allocation concealment and blinding of outcome assessment; one study was at high risk of bias for blinding of participants and personnel; two studies were at high risk of attrition bias; and three studies were at high risk of bias due to notable funding concerns. We judged the certainty of evidence (GRADE) to be moderate to very low, downgrading for study limitations, imprecision of results, and publication bias. </p> <p><b>TC compared to placebo</b> </p> <p>There was no evidence of a difference in number of participants with participant‐reported pain relief of 50% or greater during longest follow‐up period (12 weeks) between groups (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.78 to 1.86; 179 participants; 1 study; low certainty evidence). However, the number of participants with participant‐reported pain relief of 30% or greater during longest follow‐up period (8 to 12 weeks) was higher in the TC group compared with placebo (RR 1.35, 95% CI 1.03 to 1.77; 344 participants; 2 studies, very low certainty evidence). The number needed to treat for an additional beneficial outcome (NNTB) for this comparison was 8.33 (95% CI 4.3 to 50.0). Also, there was no evidence of a difference between groups for the outcomes much or very much improved on the PGIC during longest follow‐up period (12 weeks) or very much improved on PGIC during the longest follow‐up period (12 weeks) (RR 1.06, 95% CI 0.76 to 1.49 and RR 1.82, 95% CI 0.89 to 3.72, respectively; 179 participants; 1 study; low certainty evidence). We observed no evidence of a difference between groups in withdrawals due to adverse events and withdrawals due to lack of efficacy during the longest follow‐up period (12 weeks) (RR 0.34, 95% CI 0.04 to 3.18 and RR 1.01, 95% CI 0.06 to 15.92, respectively; 179 participants; 1 study; low certainty evidence) and participants experiencing at least one adverse event during longest follow‐up period (12 weeks) (RR 0.65, 95% CI 0.14 to 3.05; 344 participants; 2 studies; low certainty evidence).  </p> <p><b>TC compared to active comparator</b> </p> <p>There was no evidence of a difference in the number of participants with participant‐reported pain relief of 50% or greater during longest follow‐up period (12 weeks) between groups (RR 1.41, 95% CI 0.99 to 2.0; 139 participants; 1 study; low certainty evidence). Other outcomes were not reported. </p> </section> <section id="CD010967-sec-0007"> <h3 class="title" id="CD010967-sec-0007">Authors' conclusions</h3> <p>This is an update of a review published in 2015, for which our conclusions remain unchanged. Topical clonidine may provide some benefit to adults with painful diabetic neuropathy; however, the evidence is very uncertain. Additional trials are needed to assess TC in other neuropathic pain conditions and to determine whether it is possible to predict who or which groups of people will benefit from TC. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010967-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010967-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010967-abs-0017">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010967-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010967-abs-0015">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010967-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD010967-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010967-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD010967-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD010967-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010967-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD010967-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010967-abs-0002" lang="en"> <h3>Clonidine applied to the skin for adults with chronic neuropathic pain</h3> <p><b>Key message</b> </p> <p>We found no high certainty evidence to support the use of clonidine applied to the skin for painful diabetic neuropathy. We found no evidence for other chronic pain conditions. </p> <p><b>What did we do?</b> </p> <p>To find out how clonidine applied to the skin (topical clonidine) works in people with neuropathic pain, we searched medical databases and references of retrieved papers and registries or clinical trials. We also contacted experts in the field. Two review authors independently screened references for eligibility, extracted data, and assessed risk of bias. When necessary, we contacted trial authors to request additional information. </p> <p><b>What did we find?</b> </p> <p>We identified four studies for inclusion in the review. The studies lasted 8 weeks to 85 days and included a total of 743 participants with painful diabetic neuropathy. Clonidine (0.1% or 0.2%) was applied in gel form to the painful area two to three times daily, and was compared with placebo (dummy treatment) in three studies and with capsaicin applied to the skin in one study. </p> <p>Limitations in how the studies were conducted and reported and the small amount of evidence available means that our confidence in the results is limited. The evidence suggests that in adults with painful diabetic neuropathy, topical clonidine may provide pain relief in some people. However, topical clonidine was not better than placebo for our other outcomes. We found no evidence of a difference between topical clonidine and capsaicin applied to the skin in painful diabetic neuropathy. The information from clinical trials is not enough to judge about possible long‐term side effects of clonidine applied to the skin; however, we found that during 8 to 12 weeks of treatment there was no evidence of a difference in number of side effects between study groups. We also do not know from the included trials how clonidine works in other chronic neuropathic pain conditions. </p> <p><b>How up‐to‐date is this evidence?</b> </p> <p>The review is current to 27 October 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010967-sec-0094" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010967-sec-0094"></div> <h3 class="title" id="CD010967-sec-0095">Implications for practice</h3> <section id="CD010967-sec-0095"> <section id="CD010967-sec-0096"> <h5 class="title">For adults with chronic neuropathic pain</h5> <p>The major implication of this review for people with chronic neuropathic pain is that a higher percentage of adults with painful diabetic neuropathy (PDN) may achieve pain relief of 30% or greater when treated with topical clonidine (TC) compared with placebo (48% versus 36%); however, the evidence for this outcome is very uncertain. Eight more people would have to be treated with TC compared to placebo for one more person to achieve moderate benefit. We found no evidence on how TC works in people with other neuropathic pain conditions. </p> </section> <section id="CD010967-sec-0097"> <h5 class="title">For clinicians</h5> <p>The major implication of this review for clinicians is that TC may provide some benefit to adults with PDN; however, the available evidence is very uncertain. The percentage of participants who achieved pain relief of 50% or greater was comparable to that in placebo group, although the percentage of participants who achieved pain relief of 30% or greater was higher in the TC group compared with the placebo group (48% versus 36%). The number needed to treat for an additional beneficial outcome (NNTB) for this comparison was over 8, which means that eight more people would have to be treated with TC compared to placebo for one more person to achieve moderate benefit. Other drugs are available for treatment of individuals with PDN with lower NNTB; however, there may be circumstances when an experienced clinician may choose to use it, because the evidence does not exclude beneficial effects in a small percentage of people, especially in situations where other available therapies have failed or as part of multimodal approach to refractive pain syndromes. We found no evidence on how TC works in people with other neuropathic pain conditions. </p> <p>Some clinicians may be concerned about long‐term safety of the drug and would prefer to see more safety data. There were no differences in numbers of participants with adverse events, numbers of withdrawals due to adverse events or lack of efficacy, and overall withdrawal rate between TC and placebo; however, it is possible that differences may not have been detected due to the relatively low number of included participants and relatively short duration of the trials. As only a very small concentration of clonidine is reached in plasma during topical application (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>), it can be assumed that topical use will be associated with rather few important adverse events, although this is not certain. </p> <p>Another difficulty is that a ready‐to‐use preparation of TC is not currently available, and the drug for topical use has to be prepared by a compounding pharmacy. Moreover, TC does not have US Food and Drug Administration or European Medicines Agency approval for neuropathic pain and thus must be prescribed 'off‐label'.  </p> </section> <section id="CD010967-sec-0098"> <h5 class="title">For policymakers and funders of the intervention</h5> <p>TC may provide some benefit to adults with PDN; however, the available evidence is of very low certainty. The circumstances in which this therapy would be tried are likely only when other available treatment options have failed, or as part of a multimodal approach to refractive pain syndromes. Lack of data precludes any conclusions on the effectiveness of TC in other neuropathic pain conditions. </p> </section> </section> <h3 class="title" id="CD010967-sec-0099">Implications for research</h3> <section id="CD010967-sec-0099"> <section id="CD010967-sec-0100"> <h5 class="title">General implications</h5> <p>This review has highlighted the lack of good evidence for TC for neuropathic pain treatment. We found very low quality evidence suggesting that TC may provide some benefit to adults with PDN, although only about one out of eight people treated with the drug may achieve pain relief of 30% or greater when compared with placebo. Chronic neuropathic pain is difficult to treat, and even effective pharmaceuticals provide relief to only a minority of people. Future research might thus explore whether it is possible to predict who or which groups of people with PDN will benefit from TC.  </p> <p>Additionally, good‐quality clinical trials are needed to establish the role of TC in other neuropathic pain conditions such as postherpetic neuralgia, trigeminal neuralgia, phantom limb pain, complex regional pain syndrome, and others.  </p> <p>The treatment period of the studies included in this review was 8 to 12 weeks. Longer duration trials would be more appropriate to establish the efficacy of TC in chronic pain conditions. Moreover, trials of longer duration are needed to assess the safety of TC. Extension studies from randomised controlled trials could provide some additional evidence.  </p> </section> <section id="CD010967-sec-0101"> <h5 class="title">Design</h5> <p>The optimal future clinical trial to answer the review question should last 3 months or longer, include a minimum of 400 participants, and have a randomised, double‐blind, placebo‐controlled or parallel‐group design. Proper randomisation method, allocation concealment, and blinding of participants and personnel should be guaranteed. Detection bias should be minimised by the blinding of outcome assessment. Missing data should be managed with last observation carried forward or another reliable imputation method. Presentation of results should be clear. Non‐pharmaceutical industry‐sponsored trials would be preferred whenever possible.  </p> </section> <section id="CD010967-sec-0102"> <h5 class="title">Measurement (endpoints)</h5> <p>Future research should include outcome measures that are relevant to clinical practice. The gold standard for now is the 'responder' analysis, although this has recently been questioned (<a href="./references#CD010967-bbs2-0058" title="MboweO , GewandterJ , TurkD , DworkinR , McDermottM .Are there really only 2 kinds of people in the world? Evaluating the distribution of change from baseline in pain clinical trials. Pain2020;161(1):195-201.">Mbowe 2020</a>). It might thus be reasonable to present additional 'mean values' analysis to better reflect the real‐life situation.  </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010967-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010967-sec-0008"></div> <div class="table" id="CD010967-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Participants or population:</b> adults with painful diabetic neuropathy </p> <p><b>Settings:</b> primary care, outpatient </p> <p><b>Intervention:</b> 0.1% or 0.2% clonidine gel applied to both feet 2 to 3 times daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>NNTB<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 100<br/>(23 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.21 (0.78 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater during longest follow‐up period</p> <p>(8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> <p>(37 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35 (1.03 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (4.3 to 50.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a difference present</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Much or very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 100</p> <p>(32 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.76 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100<br/>(10 to 41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82 (0.89 to 3.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (0.04 to 3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least 1<br/>adverse event during longest follow‐up period </p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> <p>(6 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.14 to 3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to lack of efficacy</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (0.06 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*Mean baseline risk was chosen to determine the <b>assumed risk</b> in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>PGIC:</b> Patient Global Impression of Change scale; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants).<br/><sup>b</sup>Downgraded one level for serious study limitations (the studies were judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment); one level for imprecision of results (optimal information size not met: fewer than 400 participants); and one level for publication bias (fewer than 200 participants in unpublished null effect studies required to make the result clinically irrelevant).<br/><sup>c</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants, wide confidence intervals, small number of events).<br/><sup>d</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants, wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD010967-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Participants or population:</b> adults with painful diabetic neuropathy </p> <p><b>Settings:</b> tertiary care setting  </p> <p><b>Intervention:</b> 0.1% clonidine gel self administered 3 times daily on both feet </p> <p><b>Comparison:</b> 0.75% capsaicin cream self administered 3 times daily on both feet </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>NNTB<br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Topical capsaicin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 100</p> <p>(41 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.41</p> <p>(0.99 to 2.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 <br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Much or very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least 1<br/>adverse event during longest follow‐up period </p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to lack of efficacy</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*Mean baseline risk was chosen to determine the <b>assumed risk</b> in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>PGIC:</b> Patient Global Impression of Change scale; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of bias for blinding of participants and personnel and unclear risk of bias for allocation concealment, blinding of outcome assessment, and study size domains) and one level for imprecision of results (optimal information size not met: more than 50 and fewer than 199 participants per treatment arm). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010967-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010967-sec-0009"></div> <p>This review is based on a template for reviews of drugs used to relieve neuropathic pain. The aim is for all reviews to use the same methods, based on new criteria for what constitutes reliable evidence in chronic pain (<a href="./appendices#CD010967-sec-0107">Appendix 1</a>) (<a href="./references#CD010967-bbs2-0064" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al."Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150:386-9.'>Moore 2010a</a>). </p> <section id="CD010967-sec-0010"> <h3 class="title" id="CD010967-sec-0010">Description of the condition</h3> <p>Neuropathic pain comprises a wide range of pain conditions. It is defined by the International Association of the Study of Pain as "pain caused by lesion or disease of the somatosensory nervous system" (<a href="./references#CD010967-bbs2-0047" title="JensenTS , BaronR , HaanpääM , KalsoE , LoeserJD , RiceAS , et al.A new definition of neuropathic pain. Pain2011;152(10):2204-5.">Jensen 2011</a>; <a href="./references#CD010967-bbs2-0057" title="MaconeA , OtisJAD .Neuropathic pain. Seminars in Neurology2018;38(6):644-53. [PMID: 30522140]">Macone 2018</a>; <a href="./references#CD010967-bbs2-0077" title="RajaSN , CarrDB , CohenM , FinnerupNB , FlorH , GibsonS , et al.The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain2020;161(9):1976-82.">Raja 2020</a>), based on an earlier consensus meeting (<a href="./references#CD010967-bbs2-0091" title="TreedeRD , JensenTS , CampbellJN , CruccuG , DostrovskyJO , GriffinJW , et al.Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology2008;70(18):1630-5.">Treede 2008</a>). Neuropathic pain may be caused by nerve damage, but is often followed by changes in the central nervous system (<a href="./references#CD010967-bbs2-0060" title="MoissetX , BouhassiraD .Brain imaging of neuropathic pain. Neuroimaging2007;37(Suppl 1):S80-8.">Moisset 2007</a>). It tends to be chronic and may be present for months or years. It is complex (<a href="./references#CD010967-bbs2-0015" title="ApkarianAV , HashmiJA , BalikiMN .Pain and the brain: specificity and plasticity of the brain in clinical chronic pain. Pain2011;152(3 Suppl):S49-64.">Apkarian 2011</a>; <a href="./references#CD010967-bbs2-0090" title="TraceyI .Can neuroimaging studies identify pain endophenotypes in humans?Nature Reviews Neurology2011;7(3):173-81.">Tracey 2011</a>), and neuropathic pain features can be found in patients with joint pain (<a href="./references#CD010967-bbs2-0085" title="SoniA , BatraR , GwilymS , SpectorT , HartD , ArdenN , et al.Neuropathic features of joint pain: a community-based study. Arthritis &amp; Rheumatism2013;65(7):1942-9.">Soni 2013</a>). The pathomechanism of neuropathic pain differs significantly from that of nociceptive pain. Nociceptive pain is a consequence of tissue damage, whereas neuropathic pain results from maladaptive changes that can occur in injured sensory neurons and along the entire nociceptive pathway within the central nervous system, possibly leading to spontaneous pain or pain hypersensitivity. The most characteristic clinical symptoms of neuropathic pain are spontaneous pain, hyperalgesia, and allodynia; this has been easily demonstrated in various animal models (<a href="./references#CD010967-bbs2-0045" title="HurleyRW , AdamsMC , BenzonHT .Neuropathic pain: treatment guidelines and updates. Current Opinion in Anaesthesiology2013;26(5):580-7.">Hurley 2013</a>; <a href="./references#CD010967-bbs2-0057" title="MaconeA , OtisJAD .Neuropathic pain. Seminars in Neurology2018;38(6):644-53. [PMID: 30522140]">Macone 2018</a>; <a href="./references#CD010967-bbs2-0093" title="WoolfCJ , MannionRJ .Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet1999;353(9168):1959-64.">Woolf 1999</a>). </p> <p>In primary care in the UK, the incidence per 100,000 person‐years of observation has been reported as 28 (95% confidence interval (CI) 27 to 30) for postherpetic neuralgia; 27 (95% CI 26 to 29) for trigeminal neuralgia; 0.8 (95% CI 0.6 to 1.1) for phantom limb pain; and 21 (95% CI 20 to 22) for painful diabetic neuropathy (PDN) (<a href="./references#CD010967-bbs2-0040" title="HallGC , CarrollD , McQuayHJ .Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice2008;9:26.">Hall 2008</a>). Estimates vary between studies, which is often due to small sample sizes. The study of facial pain in the Netherlands found an incidence per 100,000 person‐years of 12.6 for trigeminal neuralgia and 3.9 for postherpetic neuralgia (<a href="./references#CD010967-bbs2-0053" title="KoopmanJS , DielemanJP , HuygenFJ , deMosM , MartinCG , SturkenboomMC .Incidence of facial pain in the general population. Pain2009;147(1-3):122-7.">Koopman 2009</a>). A systematic review of chronic pain indicated that some neuropathic pain conditions, such as PDN, are more common than others, with prevalence rates up to 400 per 100,000 person‐years (<a href="./references#CD010967-bbs2-0059" title="McQuayHJ , SmithLA , MooreRA .Chronic pain. In: StevensA , RafteryJ , MantJ , SimpsonS , editors(s). Health Care Needs Assessment. 3rd series edition. Oxford: Radcliffe Publishing, 2007.">McQuay 2007</a>), illustrating how common the condition is as well as its chronicity. The prevalence of neuropathic pain was reported as 8.9% in England and 8.2% in Scotland (<a href="./references#CD010967-bbs2-0032" title="FayazA , CroftP , LangfordRM , DonaldsonLJ , JonesGT .Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open2016;6:e010364.">Fayaz 2016</a>), 3.3% in Austria (<a href="./references#CD010967-bbs2-0039" title="GustorffB , DornerT , LikarR , GrisoldW , LawrenceK , SchwarzF , et al.Prevalence of self-reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica2008;52(1):132-6.">Gustorff 2008</a>), 6.9% in France (<a href="./references#CD010967-bbs2-0019" title="BouhassiraD , Lanteri-MinetM , AttalN , LaurentB , TouboulC .Prevalence of chronic pain with neuropathic characteristics in the general population. Pain2008;136:380–7.">Bouhassira 2008</a>), as high as 8% in the UK, and about 7% in a systematic review of studies published since 2000 (<a href="./references#CD010967-bbs2-0013" title="AndrewR , DerryS , TaylorRS , StraubeS , PhillipsCJ .The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94.">Andrew 2014</a>; <a href="./references#CD010967-bbs2-0089" title="TorranceN , SmithBH , BennettMI , LeeAJ .The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain2006;7(4):281–9.">Torrance 2006</a>). The incidence of some forms of neuropathic pain, such as diabetic neuropathy and postsurgical chronic pain (often neuropathic in origin), is increasing (<a href="./references#CD010967-bbs2-0020" title="BouhassiraD .Neuropathic pain: definition, assessment and epidemiology. Revue Neurologique2019;175(1-2):16-25. [PMID: 30385075]">Bouhassira 2019</a>; <a href="./references#CD010967-bbs2-0040" title="HallGC , CarrollD , McQuayHJ .Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002-2005. BMC Family Practice2008;9:26.">Hall 2008</a>). </p> <p>Neuropathic pain is known to be difficult to treat effectively; only a minority of individuals experience clinically relevant benefit from any one intervention. A multidisciplinary approach is now advocated, with pharmacological interventions combined with physical or cognitive interventions, or both. Conventional analgesics are usually not effective. Some patients may benefit from a topical lidocaine patch or low‐concentration topical capsaicin, although evidence showing benefits is uncertain (<a href="./references#CD010967-bbs2-0014" title="AnitescuM , BenzonHT , ArgoffCE .Advances in topical analgesics. Current Opinion in Anaesthesiology2013;25(5):551-61.">Anitescu 2013</a>; <a href="./references#CD010967-bbs2-0025" title="DerryS , MooreRA .Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 9. Art. No: CD010111. [DOI: 10.1002/14651858.CD010111]">Derry 2012</a>; <a href="./references#CD010967-bbs2-0049" title="KhaliqW , AlamS , PuriN .Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database of Systematic Reviews2007, Issue 2. Art. No: CD004846. [DOI: 10.1002/14651858.CD004846.pub2]">Khaliq 2007</a>). High‐concentration topical capsaicin may be helpful for some patients with postherpetic neuralgia (<a href="./references#CD010967-bbs2-0026" title="DerryS , Sven-RiceA , ColeP , TanT , MooreRA .Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 2. Art. No: CD007393. [DOI: 10.1002/14651858.CD007393.pub3]">Derry 2013</a>). Treatment more usually consists of so‐called unconventional analgesics such as antidepressants (e.g. duloxetine, amitriptyline) or antiepileptics (e.g. gabapentin, pregabalin) (<a href="./references#CD010967-bbs2-0056" title="LunnMP , HughesRA , WiffenPJ .Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115.pub2]">Lunn 2009</a>; <a href="./references#CD010967-bbs2-0063" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ .Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub2]">Moore 2009</a>; <a href="./references#CD010967-bbs2-0067" title="MooreRA , WiffenPJ , DerryS , McQuayHJ .Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. Art. No: CD007938. [DOI: 10.1002/14651858.CD007938.pub2]">Moore 2011a</a>; <a href="./references#CD010967-bbs2-0069" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ .Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 12. Art. No: CD008242. [DOI: 10.1002/14651858.CD008242.pub2]">Moore 2012</a>; <a href="./references#CD010967-bbs2-0088" title="SultanA , GaskellH , DerryS , MooreRA .Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology2008;8:29.">Sultan 2008</a>). An overview of treatment guidelines points out general similarities, as well as differences, in treatment approaches (<a href="./references#CD010967-bbs2-0017" title="BatesD , CarstenSB , HanesMC , JollySM , ChakravarthyKV , DeerTR , et al.A comprehensive algorithm for management of neuropathic pain. Pain Medicine (United States)2019;20(Suppl 1):S2-12.">Bates 2019</a>; <a href="./references#CD010967-bbs2-0045" title="HurleyRW , AdamsMC , BenzonHT .Neuropathic pain: treatment guidelines and updates. Current Opinion in Anaesthesiology2013;26(5):580-7.">Hurley 2013</a>; <a href="./references#CD010967-bbs2-0073" title="O'ConnorAB , DworkinRH .Treatment of neuropathic pain: an overview of recent guidelines. American Journal of Medicine2009;122(10 Suppl):S22-32.">O'Connor 2009</a>; <a href="./references#CD010967-bbs2-0084" title="SmithBH , LeeJ , PriceC , BaranowskiAP .Neuropathic pain: a pathway for care developed by the British Pain Society. British Journal of Anaesthesia2013;111:73-9.">Smith 2013</a>). The proportion of patients who achieve worthwhile pain relief (typically ≥ 50% reduction in pain intensity) is small, generally 10% to 25% greater than with placebo, and numbers needed to treat for additional beneficial outcome (NNTBs) are usually between four and 10 (<a href="./references#CD010967-bbs2-0070" title="MooreRA , StraubeS , AldingtonD .Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia2013;68(4):400-12.">Moore 2013</a>; <a href="./references#CD010967-bbs2-0094" title="XuL , ZhangY , HuangY .Advances in the treatment of neuropathic pain. Advances in Experimental Medicine and Biology2016;904:117-29. [PMID: 26900067]">Xu 2016</a>). </p> <p>Chronic painful conditions constantly account for top‐ranking conditions for years lived with disability (<a href="./references#CD010967-bbs2-0092" title=" GBD 2019 Diseases and Injuries Collaborators: Vos T , LimSS , AbbafatiC , AbbasK , AbbasiM , AbbasifardM , et al.Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet2020;396(10258):1204-22.">Vos 2020</a>), and are responsible for considerable loss of quality of life and employment, as well as increased healthcare costs (<a href="./references#CD010967-bbs2-0013" title="AndrewR , DerryS , TaylorRS , StraubeS , PhillipsCJ .The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94.">Andrew 2014</a>). </p> </section> <section id="CD010967-sec-0011"> <h3 class="title" id="CD010967-sec-0011">Description of the intervention</h3> <p>Clonidine is a presynaptic alpha‐2‐adrenergic receptor agonist and an agonist of imidazoline receptors (<a href="./references#CD010967-bbs2-0031" title="EisenachJC , De KockM , KlimschaW .Alpha2-adrenergic agonists for regional anesthesia: a clinical review of clonidine (1984–1995). Anesthesiology1996;85:655–74.">Eisenach 1996</a>; <a href="./references#CD010967-bbs2-0096" title="YasaeiR , SaadabadiA .Clonidine. Treasure Island (FL): StatPearls Publishing, 2021.">Yasaei 2021</a>). It has been in clinical use for over 40 years. It was first registered for treatment of hypertension, but was later shown to be effective for treatment of acute and chronic pain (<a href="./references#CD010967-bbs2-0071" title="NeilMJ .Clonidine: clinical pharmacology and therapeutic use in pain management. Current Clinical Pharmacology2011;6:280-7.">Neil 2011</a>). Clonidine is an extremely potent antinociceptive agent with potency equal to or greater than that reported for morphine (<a href="./references#CD010967-bbs2-0036" title="GentiliM , HousselP , OsmanM , HenelD , JuhelA , BonnetF .Intra-articular morphine and clonidine produce comparable analgesia but the combination is not more effective. British Journal of Anaesthesia1997;79(5):660–1.">Gentili 1997</a>; <a href="./references#CD010967-bbs2-0080" title="SamsoE , VallesJ , PolO , GallartL , PuigMM .Comparative assessment of the anaesthetic and analgesic effects of intramuscular and epidural clonidine in humans. Canadian Journal of Anesthesia1996;43(12):1195–202.">Samso 1996</a>). Clonidine has been used to treat acute and chronic pain and may be effective when applied intravenously, epidurally, and intrathecally (<a href="./references#CD010967-bbs2-0016" title="AsanoT , DohiS , OhtaS , ShimonakaH , LidaH .Antinociception by epidural and systemic alpha(2)-adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesthesia &amp; Analgesia2000;90(2):400–7.">Asano 2000</a>; <a href="./references#CD010967-bbs2-0024" title="CrespoS , DangelserG , HallerG .Intrathecal clonidine as an adjuvant for neuraxial anaesthesia during caesarean delivery: a systematic review and meta-analysis of randomised trials. International Journal of Obstetric Anesthesia2017;32:64-76.">Crespo 2017</a>; <a href="./references#CD010967-bbs2-0030" title="EisenachJC , DuPenS , DuboisM , MiguelR , AllinD , Epidural Clonidine Study Group 2.Epidural clonidine analgesia for intractable cancer pain. Pain1995;61(3):391–9.">Eisenach 1995</a>; <a href="./references#CD010967-bbs2-0041" title="HassenbuschSJ , GunesS , WachsmanS , WillisKD .Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. Pain Medicine2002;3:85–91.">Hassenbusch 2002</a>; <a href="./references#CD010967-bbs2-0083" title="SierraltaF , NaquiraD , PinardiG , MirandaHF .Alpha-adrenoceptor and opioid receptor modulation of clonidine-induced antinociception. British Journal of Pharmacology1996;119(3):551–4.">Sierralta 1996</a>). However, systemic and central use of clonidine is limited by undesirable adverse events including sedation, dry mouth, hypotension, and rebound hypertension (<a href="./references#CD010967-bbs2-0028" title="DiasVC , TendlerB , OparilS , ReillyPA , SnarP , WhiteWB .Clinical experience with transdermal clonidine in African-American and Hispanic-American patients with hypertension: evaluation from a 12-week prospective, open-label clinical trial in community-based clinics. American Journal of Therapeutics1999;6(1):19–24.">Dias 1999</a>; <a href="./references#CD010967-bbs2-0076" title="PuskasF , CamporesiEM , O'LearyCE , HauserM , NasrallahFV .Intrathecal clonidine and severe hypotension after cardiopulmonary bypass. Anesthesia &amp; Analgesia2003;97(5):1251–3.">Puskas 2003</a>). Since the beginning of the century, topical forms of administration have been developed with the intention of limiting centrally mediated adverse events without reduction in analgesic efficacy (<a href="./references#CD010967-bbs2-0081" title="SawynokJ .Topical and peripherally acting analgesics. Pharmacological Reviews2003;55(1):1–20.">Sawynok 2003</a>). Clonidine is lipophilic and easily penetrates the skin to reach the local antinociceptive pathways. The half‐life of clonidine is about eight hours, thus it should be applied three times daily. Clonidine can be prepared in various concentrations by compounding pharmacies (<a href="./references#CD010967-bbs2-0027" title="DerryS , WiffenPJ , KalsoEA , BellRF , AldingtonD , PhillipsT , et al.Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database of Systematic Reviews2017, Issue 5. Art. No: CD008609. [DOI: 10.1002/14651858.CD008609.pub2] [PMID: 28497473]">Derry 2017</a>; <a href="./references#CD010967-bbs2-0034" title="FloresMP , CastroAP , Nascimento JdosS .Topical analgesics. Revista Brasileira de Anestesiologia2012;62(2):244-52.">Flores 2012</a>; <a href="./references#CD010967-bbs2-0075" title="PaganoniS .Evidence-based physiatry: topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. American Journal of Physical Medicine &amp; Rehabilitation2018;97(7):531-2. [PMID: 29916902]">Paganoni 2018</a>). </p> <p>Several animal studies have shown that topical clonidine (TC) may be an effective analgesic. Dogrul and colleagues demonstrated that topical administration of clonidine increased the pain threshold to radiant heat stimuli (measured by tail‐flick test) in mice. Antinociceptive activity was limited to the portion of the tail exposed to drug solution. Systemic administration of the alpha‐2‐receptor antagonist yohimbine before immersion of the tail blocked the antinociceptive activity of TC (<a href="./references#CD010967-bbs2-0029" title="DogrulA , UzbayIT .Topical clonidine antinociception. Pain2004;111(3):385-91.">Dogrul 2004</a>). Chi and colleagues studied the efficacy of topically applied clonidine in an animal model of neuropathic, postoperative, and inflammatory pain. Clonidine was effective in neuropathic pain, only partially effective in postoperative pain, and not effective in inflammatory pain. The analgesic efficacy of clonidine in postoperative pain manifested on the sixth day of application, and reduction in thermal hyperalgesia ‐ not mechanical allodynia ‐ was observed (<a href="./references#CD010967-bbs2-0023" title="ChiL , SekiyamaH , HayashidaM , TakedaK , SumidaT , SawamuraS , et al.Effects of topical application of clonidine cream on pain behaviors and spinal Fos protein expression in rat models of neuropathic pain, postoperative pain, and inflammatory pain. Anesthesiology2007;107(3):486-94.">Chi 2007</a>). </p> </section> <section id="CD010967-sec-0012"> <h3 class="title" id="CD010967-sec-0012">How the intervention might work</h3> <p>Target receptors for clonidine ‐ alpha‐2 receptors ‐ are located in the brain, spinal cord, and dorsal root ganglia and on sensory neurons (<a href="./references#CD010967-bbs2-0048" title="KawasakiY , KumamotoE , FurueH , YoshimuraM .Alpha 2 adrenoceptor mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons. Anesthesiology2003;98(3):682–9.">Kawaski 2003</a>; <a href="./references#CD010967-bbs2-0074" title="OngiocoRR , RichardsonCD , RudnerXL , Stafford-SmithM , SchwinnDA .Alpha2-adrenergic receptors in human dorsal root ganglia: predominance of alpha2b and alpha2c subtype mRNSs. Anesthesiology2000;92(4):968–76.">Ongioco 2000</a>; <a href="./references#CD010967-bbs2-0079" title="RiedlMS , SchnellSA , OverlandAC , Chabot-DoréAJ , TaylorAM , Ribeiro-da-SilvaA , et al.Coexpression of alpha 2A-adrenergic and delta-opioid receptors in substance P-containing terminals in rat dorsal horn. Journal of Comparative Neurology2009;513:385–98.">Riedl 2009</a>). Activation of alpha‐2 receptors leads to release of an inhibitory G‐protein, which down‐regulates adenylate cyclase and other second messengers responsible for initiating and maintaining the abnormal excitability of nociceptors (<a href="./references#CD010967-bbs2-0054" title="Lavand‘hommePM , MaW , DeKM , EisenachJC .Perineural alpha(2A)-adrenoceptor activation inhibits spinal cord neuroplasticity and tactile allodynia after nerve injury. Anesthesiology2002;97:972–80.">Lavand'homme 2002</a>). Antinociceptive effects of clonidine are mediated via spinal and supraspinal sites of action (<a href="./references#CD010967-bbs2-0016" title="AsanoT , DohiS , OhtaS , ShimonakaH , LidaH .Antinociception by epidural and systemic alpha(2)-adrenoceptor agonists and their binding affinity in rat spinal cord and brain. Anesthesia &amp; Analgesia2000;90(2):400–7.">Asano 2000</a>; <a href="./references#CD010967-bbs2-0018" title="BernardJM , KickO , BonnetF .Which way for the administration of alpha2-adrenergic agents to obtain the best analgesia?Cahiers d Anesthésiologie1994;42(2):223–8.">Bernard 1994</a>; <a href="./references#CD010967-bbs2-0021" title="BuerkleH , YakshTL .Pharmacological evidence for different alpha2-adrenergic receptor sites mediating analgesia and sedation in the rat. British Journal of Anaesthesia1998;81(2):208–15.">Buerkle 1998</a>). However, investigators in previous studies showed that peripheral administration of alpha‐2‐receptor agonists also induces antinociception (<a href="./references#CD010967-bbs2-0012" title="AleyKO , LevineJD .Multiple receptors involved in peripheral alpha 2, mu, and A1 antinociception, tolerance, and withdrawal. Journal of Neuroscience1997;17(2):735–44.">Aley 1997</a>; <a href="./references#CD010967-bbs2-0021" title="BuerkleH , YakshTL .Pharmacological evidence for different alpha2-adrenergic receptor sites mediating analgesia and sedation in the rat. British Journal of Anaesthesia1998;81(2):208–15.">Buerkle 1998</a>; <a href="./references#CD010967-bbs2-0022" title="BuerkleH .Peripheral antinociceptive action of alpha2-adrenoceptoragonist. Baillière's Clinical Anaesthesiology2000;2:411–8.">Buerkle 2000</a>; <a href="./references#CD010967-bbs2-0035" title="GentiliM , JuhelA , BonnetF .Peripheral analgesic effect of intra-articular clonidine. Pain1996;64(3):593–6.">Gentili 1996</a>). The mechanism of action of clonidine is similar to that of opioids. Antinociceptive effects of topically administered opioids have been previously reported (<a href="./references#CD010967-bbs2-0051" title="KolesnikovYA , PasternakGW .Topical opioid in mice: analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. Journal of Pharmacology and Experimental Therapeutics1999;290:247–52.">Kolesnikov 1999</a>; <a href="./references#CD010967-bbs2-0052" title="KolesnikovYA , ChereshnevI , PasternakGW .Analgesic synergy between topical lidocaine and topical opioids. Journal of Pharmacology and Experimental Therapeutics2000;295:546-51.">Kolesnikov 2000</a>); however, tolerance to antinociceptive action was observed after repeated administration (<a href="./references#CD010967-bbs2-0051" title="KolesnikovYA , PasternakGW .Topical opioid in mice: analgesia and reversal of tolerance by a topical N-methyl-D-aspartate antagonist. Journal of Pharmacology and Experimental Therapeutics1999;290:247–52.">Kolesnikov 1999</a>). Tolerance to the antinociceptive action of clonidine was observed in animal studies and was not attenuated by N‐Methyl‐D‐aspartate (NMDA)‐receptor antagonists such as ketamine (<a href="./references#CD010967-bbs2-0029" title="DogrulA , UzbayIT .Topical clonidine antinociception. Pain2004;111(3):385-91.">Dogrul 2004</a>). </p> <p>Clonidine is also an imidazoline‐receptor agonist. Stimulation of the I<sub>2</sub>‐imidazoline subclass of receptors causes analgesia. I<sub>2</sub>‐imidazoline receptors are located centrally in the brain and spinal cord and peripherally on peripheral nerve endings. Activation of peripheral imidazoline receptors may be responsible for additional mechanisms of analgesic activity of TC (<a href="./references#CD010967-bbs2-0050" title="KhanZP , FergusonCN , JonesRM .Alpha-2 and imidazoline receptor agonists. Their pharmacology and therapeutic role. Anaesthesia1999;54(2):146-65.">Khan 1999</a>). </p> </section> <section id="CD010967-sec-0013"> <h3 class="title" id="CD010967-sec-0013">Why it is important to do this review</h3> <p>Practitioners have for many years attempted to use TC to treat neuropathic pain; however, no clear evidence is available to support this clinical practice. In the last 20 years, new randomised clinical trials investigating this topic have been published. The aim of this review was to determine whether TC is effective in neuropathic pain, and to specify in which neuropathic pain conditions in particular it is effective. This topic has not been examined in another Cochrane Review. </p> <p>Standards used to assess evidence in chronic pain trials have changed substantially, with particular attention paid to trial duration, withdrawals, and statistical imputation following withdrawal ‐ all of which can substantially alter estimates of efficacy. The most important change is the move from use of average pain scores, or average change in pain scores, to the numbers of study participants who report a large decrease in pain (≥ 50%); this level of pain relief has been shown to correlate with improvement in comorbid symptoms, function, and quality of life (<a href="./references#CD010967-bbs2-0037" title="GewandterJS , DworkinRH , TurkDC , FarrarJT , FillingimRB , GilronI , et al.Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain2015;156(7):1184-97.">Gewandter 2015</a>). </p> <p>This Cochrane Review was designed to assess evidence in ways that make both statistical and clinical sense, and to use developing criteria for what constitutes reliable evidence in chronic pain (<a href="./references#CD010967-bbs2-0064" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al."Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain2010;150:386-9.'>Moore 2010a</a>). Trials included and analysed had to meet minimum criteria for reporting quality (blinding, randomisation), validity (duration, dose and timing, diagnosis, outcomes, etc.), and size (ideally ≥ 500 participants in a comparison in which the NNTB is ≥ 4) (<a href="./references#CD010967-bbs2-0061" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ .Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16.">Moore 1998</a>). This approach imposes high standards and marks a departure from the way previous reviews were conducted. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010967-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010967-sec-0014"></div> <p>The objective of this review was to assess the analgesic efficacy and safety of TC compared with placebo or other drugs in adults aged 18 years or above with chronic neuropathic pain. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010967-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010967-sec-0015"></div> <section id="CD010967-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010967-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials with double‐blind assessment of outcomes following two weeks of treatment or longer. Randomised trials are the optimal design for minimising bias when evaluating the effectiveness of an intervention, and a two‐week treatment period is considered a minimum treatment time to assess the efficacy of drugs in chronic pain conditions. Cross‐over studies were also eligible for inclusion, provided results for the first phase were reported clearly. We required full journal publications, with the exception of online clinical trial results summaries of otherwise unpublished clinical trials and abstracts with sufficient data for analysis. We did not include short abstracts (usually meeting reports). We excluded studies that were non‐randomised, experimental studies using pain induction, case reports, and clinical observations. We applied no language restrictions. </p> </section> <section id="CD010967-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults aged 18 years or above. Participants had to have one or more of a wide range of chronic (lasting over three months) neuropathic pain conditions, including the following. </p> <p> <ul id="CD010967-list-0001"> <li> <p>Painful diabetic neuropathy</p> </li> <li> <p>Postherpetic neuralgia</p> </li> <li> <p>Trigeminal neuralgia</p> </li> <li> <p>Phantom limb pain</p> </li> <li> <p>Postoperative or traumatic neuropathic pain</p> </li> <li> <p>Complex regional pain syndrome</p> </li> <li> <p>Cancer‐related neuropathy</p> </li> <li> <p>HIV neuropathy</p> </li> <li> <p>Spinal cord injury</p> </li> </ul> </p> </section> <section id="CD010967-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Topical clonidine had to be administered to a painful area for relief of neuropathic pain in a form of cream, ointment, gel, patch, or plaster and compared with placebo or any active comparator. We included studies in which placebo or the comparator was administered via any route: topically, orally, intravenously, subcutaneously, etc. We did not include studies where clonidine was applied transdermally with the intention of producing a systemic effect, not a local effect. </p> </section> <section id="CD010967-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We anticipated that studies would use a variety of outcome measures, with most studies employing standard subjective scales (numerical rating scale (NRS) or visual analogue scale (VAS)) for pain intensity or pain relief, or both. We were particularly interested in Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT) definitions of moderate and substantial benefit in chronic pain studies (<a href="./references#CD010967-bbs2-0037" title="GewandterJS , DworkinRH , TurkDC , FarrarJT , FillingimRB , GilronI , et al.Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. Pain2015;156(7):1184-97.">Gewandter 2015</a>). Benefit is defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on the Patient Global Impression of Change scale (PGIC) (moderate), and very much improved on the PGIC (substantial). These outcomes differ from those used in some other reviews, concentrating as they do on continuous outcomes, when pain responses do not follow a normal (Gaussian) distribution. People with chronic pain desire high levels of pain relief, ideally more than 50%, and pain not worse than mild (<a href="./references#CD010967-bbs2-0072" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al.Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6-15.">O'Brien 2010</a>). </p> <section id="CD010967-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010967-list-0002"> <li> <p>Participant‐reported pain relief of 50% or greater during longest follow‐up period</p> </li> <li> <p>Participant‐reported pain relief of 30% or greater during longest follow‐up period</p> </li> <li> <p>Much or very much improved on PGIC during longest follow‐up period</p> </li> <li> <p>Very much improved on PGIC during longest follow‐up period</p> </li> </ul> </p> </section> <section id="CD010967-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010967-list-0003"> <li> <p>Withdrawals due to adverse events during longest follow‐up period</p> </li> <li> <p>Participants experiencing at least one adverse event during longest follow‐up period</p> </li> <li> <p>Withdrawals due to lack of efficacy during longest follow‐up period</p> </li> <li> <p>Participants experiencing at least one serious adverse event during longest follow‐up period. Serious adverse events typically include any untoward medical occurrence or effect that at any dose results in death, is life‐threatening, requires hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is an ‘important medical event’ that may jeopardise the participant or may require an intervention to prevent one of the above characteristics/consequences. </p> </li> <li> <p>Specific adverse events, in particular somnolence and dizziness during longest follow‐up period </p> </li> <li> <p>Any pain‐related outcome indicating some improvement during longest follow‐up period (including physical and emotional functioning) </p> </li> <li> <p>Skin biopsy results</p> </li> <li> <p>Change in average pain intensity during longest follow‐up period</p> </li> </ul> </p> </section> </section> </section> <section id="CD010967-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010967-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for this update.</p> <p> <ul id="CD010967-list-0004"> <li> <p>Cochrane Register of Studies Online (CRSO), 17 September 2014 to 27 October 2021</p> </li> <li> <p>MEDLINE and MEDLINE in Process (Ovid), September 2014 to 27 October 2021</p> </li> <li> <p>Embase (Ovid), September 2014 to 2021 week 43</p> </li> </ul> </p> <p>We used medical subject headings (MeSH) or equivalent and text word terms and applied no language restrictions. We tailored searches to individual databases; our search strategies are provided in <a href="./appendices#CD010967-sec-0108">Appendix 2</a>, <a href="./appendices#CD010967-sec-0109">Appendix 3</a>, and <a href="./appendices#CD010967-sec-0110">Appendix 4</a>. The most recent search was performed on 27 October 2021. The search strategy wad developed by the Pain, Palliative and Supportive Care Group (PaPaS) Review Group’s Information Specialist and was independently peer reviewed. The PaPaS Information Specialist performed the searches. </p> </section> <section id="CD010967-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched the following trial registers on 27 October 2021 for ongoing trials.</p> <p> <ul id="CD010967-list-0005"> <li> <p><i>meta</i> Register of controlled trials (<i>m</i>RCT) (<a href="http://www.controlled-trials.com/mrct/" target="_blank">www.controlled-trials.com/mrct/</a>) </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) </p> </li> </ul> </p> <p>In addition, we searched the grey literature, checked the reference lists of reviews and retrieved articles for additional studies, and searched citations on key articles. We contacted experts in the field to ask about unpublished and ongoing trials, and contacted investigators or study sponsors when necessary. </p> </section> </section> <section id="CD010967-sec-0026"> <h3 class="title" id="CD010967-sec-0026">Data collection and analysis</h3> <section id="CD010967-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We determined study eligibility by reading the abstract of each study identified by the search. We eliminated studies that clearly did not satisfy our inclusion criteria; these decisions were made by five review authors (WS, RZ, AW, JJ, J Woron). We obtained the full texts of studies identified as potentially relevant by at least one review author. Two review authors (AW, WS) independently read the full texts of these studies and decided whether or not they met the inclusion criteria. In cases of disagreement, review authors reached conclusions by discussion or by seeking the opinion of a third review author (J Wordliczek or JD, JJ) if necessary. We did not anonymise the studies in any way before assessment. We created a PRISMA flow diagram to document the screening process (<a href="./references#CD010967-bbs2-0055" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al.The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700.">Liberati 2009</a>), as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010967-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>). We included studies in the review irrespective of whether measured outcome data were reported in a 'useable' way. </p> </section> <section id="CD010967-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (WS, AW) independently extracted data from the studies using a standard, piloted data extraction form (<a href="./appendices#CD010967-sec-0111">Appendix 5</a>). Any disagreements were resolved by consultation and discussion with a third review author (J Wordliczek). One review author (WS) entered data into Cochrane statistical software Review Manager Web (<a href="./references#CD010967-bbs2-0078" title="Review Manager Web (RevMan Web).Version 3.0.1. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>), and another review author (AW) checked the data for accuracy. We collated multiple reports of the same study so that each study, rather than each report, was the unit of interest in the review. We collected characteristics of the included studies in sufficient detail to populate a 'Characteristics of included studies' table. We included the following data when available. </p> <p> <ul id="CD010967-list-0006"> <li> <p>Study design (including methods, location, funding sources, study author declarations of interest) </p> </li> <li> <p>Setting</p> </li> <li> <p>Participants (including inclusion criteria, exclusion criteria, number of participants screened/enrolled/randomly assigned to each treatment arm, age, number of males, duration of pain condition, mean baseline pain intensity) </p> </li> <li> <p>Intervention (including form of application, place of application, concentration, dose, dosing regimen) </p> </li> <li> <p>Comparator (including form of application, place of application, concentration, dose, dosing regimen) </p> </li> <li> <p>Outcomes (including measures and time points)</p> </li> <li> <p>Numerical data for outcomes of interest</p> </li> <li> <p>Other important information</p> </li> </ul> </p> </section> <section id="CD010967-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used the Oxford Quality Score as the basis for inclusion (<a href="./references#CD010967-bbs2-0046" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?Controlled Clinical Trials1996;17(1):1-12.">Jadad 1996</a>), limiting inclusion to studies that were at a minimum randomised and double‐blind. </p> <p>Two review authors (WS, AW) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010967-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>). Any disagreements were resolved by discussion. We completed a risk of bias table for each included study using the risk of bias tool in Review Manager Web (<a href="./references#CD010967-bbs2-0078" title="Review Manager Web (RevMan Web).Version 3.0.1. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). </p> <p>We assessed the following biases for each included study.</p> <p> <ul id="CD010967-list-0007"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as follows. </p> <ul id="CD010967-list-0008"> <li> <p>Low risk of bias (any truly random process, e.g. random number table, computer random number generator) </p> </li> <li> <p>Unclear risk of bias (insufficient detail about the method of randomisation to permit a judgement of 'low' or 'high' risk of bias) </p> </li> <li> <p>We excluded studies using a non‐random process (e.g. odd or even date of birth; hospital or clinic record number) </p> </li> </ul> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions before assignment determines whether intervention allocation could have been foreseen in advance of, or during, recruitment, or changed after assignment. We assessed methods as follows. </p> <ul id="CD010967-list-0009"> <li> <p>Low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes) </p> </li> <li> <p>Unclear risk of bias (insufficient detail about the method of randomisation to permit a judgement of 'low' or 'high' risk of bias) </p> </li> <li> <p>We excluded studies that did not conceal allocation (e.g. open list)</p> </li> </ul> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed methods used to blind study participants and personnel from the knowledge of which intervention a participant received. We assessed these methods as follows. </p> <ul id="CD010967-list-0010"> <li> <p>Low risk of bias (study states that it was blinded and describes the method used to achieve blinding, e.g. identical form of cream or gel; matched in appearance and smell, or a double‐dummy technique) </p> </li> <li> <p>Unclear risk of bias (study states that it was blinded but does not provide an adequate description of how this was achieved) </p> </li> <li> <p>We considered studies that were not double‐blind to have high risk of bias</p> </li> </ul> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed methods used to blind outcome assessors from the knowledge of which intervention a participant received. We assessed these methods as follows. </p> <ul id="CD010967-list-0011"> <li> <p>Low risk of bias (study states clearly that outcome assessors were unaware of treatment allocation, ideally describing how this was achieved) </p> </li> <li> <p>Unclear risk of bias (study states that outcome assessors were blind to treatment allocation, but a clear statement on how this was achieved is lacking) </p> </li> <li> <p>High risk of bias (outcome assessment was not blinded)</p> </li> </ul> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed methods used to deal with incomplete data as follows. </p> <ul id="CD010967-list-0012"> <li> <p>Low risk (no missing outcome data; reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; missing data have been imputed using 'baseline observation carried forward’ analysis) </p> </li> <li> <p>Unclear risk of bias (insufficient reporting of attrition/exclusions to permit a judgement of 'low' or 'high' risk of bias (e.g. number randomised not stated, no reasons for missing data provided, or the study does not address this outcome) </p> </li> <li> <p>High risk of bias (reason for missing outcome data is likely to have been related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; ‘as‐treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation) </p> </li> </ul> </li> <li> <p>Selective reporting (checking for reporting bias). We assessed reporting biases due to selective outcome reporting. We judged studies as follows. </p> <ul id="CD010967-list-0013"> <li> <p>Low risk of bias (the study protocol is available, and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way) </p> </li> <li> <p>Unclear risk of bias (insufficient information available to permit a judgement of 'low' or 'high' risk of bias) </p> </li> <li> <p>High risk of bias (not all the study’s prespecified primary outcomes have been reported; one or more primary outcomes have been reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified; one or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review have been reported incompletely so that they cannot be entered in a meta‐analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study) </p> </li> </ul> </li> <li> <p>Study size (checking for possible biases confounded by small size). Based on methodology proposed by the ACTINPAIN Cochrane Special Interest Group (<a href="./references#CD010967-bbs2-0067" title="MooreRA , WiffenPJ , DerryS , McQuayHJ .Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2011, Issue 3. Art. No: CD007938. [DOI: 10.1002/14651858.CD007938.pub2]">Moore 2011a</a>), we judged studies as follows. </p> <ul id="CD010967-list-0014"> <li> <p>Low risk of bias (≥ 200 participants per treatment arm)</p> </li> <li> <p>Unclear risk of bias (50 to 199 participants per treatment arm)</p> </li> <li> <p>High risk of bias (&lt; 50 participants per treatment arm)</p> </li> </ul> </li> <li> <p>Funding bias. We judged studies as follows.</p> <ul id="CD010967-list-0015"> <li> <p>Low risk of bias (no notable concerns, e.g. funding by governmental institution)</p> </li> <li> <p>High risk of bias (notable concerns, e.g. funding by pharmaceutical company)</p> </li> <li> <p>Unclear risk of bias (funding source not disclosed)</p> </li> </ul> </li> </ul> </p> </section> <section id="CD010967-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used dichotomous data to calculate risk ratio (RR) and number needed to treat for an additional beneficial outcome (NNTB) with 95% confidence intervals (CIs) to establish statistical differences. We calculated NNTBs as the reciprocal of absolute risk reduction (ARR). For unwanted effects, the NNTB becomes the number needed to treat for an additional harmful outcome (NNTH), which is calculated in the same manner. We used a fixed‐effect model, unless we found significant statistical heterogeneity (see <a href="#CD010967-sec-0035">Data synthesis</a>). Given that the amount of evidence was small, we decided to include a continuous outcome for illustrative purposes only, and presented data as mean difference (MD) with P value. We considered P values equal to or less than 0.05 (two‐sided alpha) as statistically significant. </p> </section> <section id="CD010967-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We accepted randomisation by individual participant only.</p> <p>We accepted cross‐over studies only if clear reporting for the first cross‐over phase was available. </p> <p>We planned to split the control treatment arm between active treatment arms in a single study in which active treatment arms were not combined for analysis; however, this was not the case in this review. </p> </section> <section id="CD010967-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We used intention‐to‐treat (ITT) analysis when the ITT population consisted of participants who were randomly assigned, took at least one dose of assigned study medication, and provided at least one postbaseline assessment. We assigned missing participants zero improvement. </p> </section> <section id="CD010967-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>As a first step, we determined whether clinical heterogeneity was significant between studies. We assessed clinical heterogeneity by comparing participants, interventions, and outcomes amongst studies. If we found significant discrepancies between studies, we did not report the pooled effect. </p> <p>If we found no clear evidence of clinical heterogeneity, we assessed quantified statistical heterogeneity between trials by calculating the I<sup>2</sup> statistic, which describes the percentage of total variation across studies due to heterogeneity rather than to chance, per Chapter 10 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010967-bbs2-0043" title="DeeksJJ , HigginsJPT ,  AltmanDG , SchünemannHJ , VistGE , GlasziouP , et al.Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>). We regarded statistical heterogeneity as low if the I<sup>2</sup> statistic was less than 30%, moderate if between 30% and 50%, substantial if between 50% and 75%, and considerable if above 75%, per Chapter 10 of the <i>Cochrane Handbook</i> (<a href="./references#CD010967-bbs2-0043" title="DeeksJJ , HigginsJPT ,  AltmanDG , SchünemannHJ , VistGE , GlasziouP , et al.Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021b</a>). We planned that if we found evidence of heterogeneity, we would investigate and report possible reasons for it. In the case of considerable heterogeneity, we would not report the pooled effect. </p> </section> <section id="CD010967-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed publication bias using a method designed to detect the quantity of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB of 10 or higher in this condition) (<a href="./references#CD010967-bbs2-0062" title="MooreRA , BardenJ , DerryS , McQuayHJ .Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ 978–0–931092–69–5]">Moore 2008</a>). We considered that fewer than 200 participants in unpublished null effect studies could give rise to doubts about the impact of efficacy results. </p> <p>The aim of this review was to use dichotomous data of known utility (<a href="./references#CD010967-bbs2-0065" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ .Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4.">Moore 2010b</a>). The review does not depend on what authors of the original studies chose to report, although clearly difficulties could arise in studies that failed to report dichotomous results. For illustrative purposes, we added a continuous outcome, that is change in average pain intensity as reported by participants using the numerical rating scale (NRS), which, however, poorly reflects efficacy and utility. </p> </section> <section id="CD010967-sec-0035"> <h4 class="title">Data synthesis</h4> <p>When at least two studies performed similar comparisons and reported the same outcome measures, and heterogeneity indicated that reporting the pooled effect was appropriate, we performed meta‐analyses using Review Manager Web (<a href="./references#CD010967-bbs2-0078" title="Review Manager Web (RevMan Web).Version 3.0.1. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>). We used a fixed‐effect model for meta‐analysis when we considered that heterogeneity was not important or low. If we found moderate or greater heterogeneity amongst studies, we used a random‐effects model (<a href="./references#CD010967-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>). We calculated 95% CIs, and considered corresponding P values equal to or less than 0.05 (two‐sided alpha) as statistically significant. </p> </section> <section id="CD010967-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned all analyses according to individual painful conditions because placebo response rates with the same outcome can vary between conditions, as can drug‐specific effects (<a href="./references#CD010967-bbs2-0063" title="MooreRA , StraubeS , WiffenPJ , DerryS , McQuayHJ .Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews2009, Issue 3. Art. No: CD007076. [DOI: 10.1002/14651858.CD007076.pub2]">Moore 2009</a>). However, insufficient data precluded the performance of any meaningful subgroup analysis. </p> </section> <section id="CD010967-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan and did not conduct sensitivity analysis because we expected the evidence to be too limited to allow reliable analysis. Also, sensitivity analyses based on different concentrations of drug were not possible. </p> </section> <section id="CD010967-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>Three review authors (WS, AW, JJ) independently rated the certainty of the body of evidence for the outcomes. We used the GRADE system to rank the certainty of the evidence, employing GRADEpro GDT software and the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and GRADE Handbook (<a href="./references#CD010967-bbs2-0038" title="GRADEpro GDT.Version accessed 5 March 2022. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD010967-bbs2-0044" title="SchünemannHJ , HigginsJPT , VistGE , GlasziouP , AklEA , SkoetzN , et al.Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021c</a>; <a href="./references#CD010967-bbs2-0082" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s).Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>). </p> <p>The GRADE approach uses five considerations (study limitations (risk of bias), unexplained heterogeneity and inconsistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of the body of evidence for each outcome. The GRADE system uses the following criteria for assigning grade of evidence. </p> <p> <ul id="CD010967-list-0016"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>The GRADE system considers study design as a marker of quality. Randomised controlled trials are considered to be high certainty evidence, and can be downgraded for important limitations. The following are factors that can decrease the certainty level of a body of evidence. </p> <p> <ul id="CD010967-list-0017"> <li> <p>Serious or very serious study limitations (risk of bias)</p> </li> <li> <p>Important or serious inconsistency of results</p> </li> <li> <p>Some or major indirectness of evidence</p> </li> <li> <p>Serious or very serious imprecision</p> </li> <li> <p>Probability of publication bias</p> </li> </ul> </p> <p>We included summary of findings tables to present the main findings for the comparisons topical clonidine (TC) versus placebo and TC versus active comparator in a transparent and simple tabular format. In particular, we included key information concerning the certainty of evidence, the magnitude of effect of the interventions examined, and the sum of available data on the following outcomes. </p> <p> <ul id="CD010967-list-0018"> <li> <p>Participant‐reported pain relief of 50% or greater</p> </li> <li> <p>Participant‐reported pain relief of 30% or greater</p> </li> <li> <p>Much or very much improved on PGIC</p> </li> <li> <p>Very much improved on PGIC</p> </li> <li> <p>Withdrawals due to adverse events</p> </li> <li> <p>Participants experiencing at least one adverse event</p> </li> <li> <p>Withdrawals due to lack of efficacy</p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010967-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010967-sec-0039"></div> <section id="CD010967-sec-0040"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD010967-sec-0123" title="">Characteristics of included studies</a> and <a href="./references#CD010967-sec-0124" title="">Characteristics of excluded studies</a> tables. </p> <section id="CD010967-sec-0041"> <h4 class="title">Results of the search</h4> <p>Our updated search period extended from September 2014 to 27 October 2021. We identified 478 records from the database searches and 11 additional records through other sources. After de‐duplication, we screened 390 records, of which 4 full‐text articles were assessed for eligibility. Four studies (two new at this update: <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>) involving a total of 743 participants were eligible for inclusion in the review (see <a href="./references#CD010967-sec-0123" title="">Characteristics of included studies</a>). We excluded six (two from the most recent search) ineligible studies (see Characteristics of excluded studies). We identified one ongoing study (see Characteristics of ongoing studies). A flow diagram outlining the trial screening and selection process is presented in <a href="#CD010967-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD010967-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD010967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD010967-sec-0042"> <h4 class="title">Included studies</h4> <p>All of the included studies were published in English. Three studies were conducted in the USA and one in Iran. Two studies were conducted by the same first author. All four studies assessed the efficacy and safety of topically applied clonidine gel in adult participants with painful diabetic neuropathy (PDN). Three studies compared TC with placebo, and one study compared TC with topical capsaicin. The total number of participants in all four studies was 743. </p> <p>The study of <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> was reported only in abstract form. We contacted the study authors and obtained additional unpublished information. In this study, investigators applied gel to both feet twice daily for two weeks, then three times daily for eight weeks total. A total of 54 participants received 650 µL of 0.1% TC per foot, and another 54 participants received 500 µL of 0.2% clonidine per foot. The control group (57 participants) was given matching placebo. </p> <p>In <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>, 91 participants were allocated to the clonidine group and received 650 µg of 0.1% clonidine gel three times daily for 12 weeks. The control group (91 participants) received matching placebo. One participant in each group did not receive the allocated intervention because these participants were found to be ineligible after randomisation. One participant in the clonidine group was excluded from the ITT population because no baseline NRS score was obtained. During the screening phase of the study, researchers assessed nociceptor function by determining pain response to 0.1% topical capsaicin applied to the pretibial area for 30 minutes. Capsaicin responders were defined as participants with pain intensity of 2 or more points on the NRS during capsaicin stimulation; investigators identified 33 such individuals in the clonidine group and 30 in the placebo group. </p> <p>In <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>, 130 participants were allocated to the clonidine group and received 0.1% clonidine gel, two times daily to both feet for 85 days. The control group (130 participants) received matching placebo. Thirteen participants in the TC group and 16 in the placebo group did not complete the study. The study was reported only as unpublished data. </p> <p>In <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>, 70 participants were allocated to the TC group and received 0.1% clonidine gel administered three times daily for 12 weeks on both feet. The control group (69 participants) received 0.75% capsaicin cream administered three times daily on both feet. Sixteen participants in the TC group and 30 in the topical capsaicin group did not complete the study. </p> <p>Baseline participant characteristics did not differ significantly between groups in all studies. More than 80% of participants had type 2 diabetes. In <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>, mean duration of diabetes was approximately 10 years, and mean duration of pain was approximately three years; mean baseline pain intensity was about 6.5 points on the NRS. In <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>, mean duration of diabetes was approximately 10.5 years in the TC group and 8.5 years in the topical capsaicin group, and mean duration of pain was approximately 21 months in the TC group and 18 months in the topical capsaicin group; mean baseline pain intensity was about 7.5 points on the visual analogue scale (VAS). <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> and <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a> did not provide this information. </p> <p>A biotechnology company, Arcion Therapeutics, supported two of the included studies (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>), and a pharmaceutical company, BioDelivery Sciences International, supported one study (<a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a> was funded by a grant from Hamedan University of Medical Sciences. In one study authors declared conflicts of interest (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>). The authors of <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a> declared no conflicts of interest. The authors of the other two included studies did not provide information on conflict of interest (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). </p> </section> <section id="CD010967-sec-0043"> <h4 class="title">Excluded studies</h4> <p>We excluded six potentially relevant studies from the analysis. Reasons for exclusion included lack of a control group in two studies (<a href="./references#CD010967-bbs2-0007" title="DavisKD , TreedeRD , RajaSN , MeyerRA , CampbellJN .Topical application of clonidine relieves hyperalgesia in patients with sympathetically maintained pain. Pain1991;47(3):309-17. ">Davis 1991</a>; <a href="./references#CD010967-bbs2-0009" title="MenoA , AritaH , HanaokaK .Preliminary report: the efficacy of clonidine hydrochloride ointment for postherpetic neuralgia. Masui - Japanese Journal of Anesthesiology2001;50(2):160-3. ">Meno 2001</a>); transdermal (not topical) drug delivery in three studies (<a href="./references#CD010967-bbs2-0006" title="Byas-SmithMG , MaxMB , MuirJ , KingmanACN .Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain1995;60(3):267-74. ">Byas‐Smith 1995</a>; <a href="./references#CD010967-bbs2-0008" title="LaurettiGR , MattosAL , LimaICPR , MatsumotoM , ResendeCS .The clinical and laboratorial evaluation of transdermal ketamine, fentanyl, clonidine or their combination in chronic low back pain. European Journal of Pain2009;13:S126. ">Lauretti 2009</a>; <a href="./references#CD010967-bbs2-0010" title="ZeiglerD , LynchSA , MuirJ , BenjaminJ , MaxMBCN .Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain1992;48(3):403-8. ">Zeigler 1992</a>); and TC used in combination with other drugs in one study (<a href="./references#CD010967-bbs2-0005" title="BrutcherR , KuriharaC , BicketM , Moussavian-YousefiP , ReeceD , SolomonL , et al.Compounded topical pain creams to treat localized chronic pain: a randomized controlled trial. Annals of Internal Medicine2019;170(5):309-18. ">Brutcher 2019</a>). Transdermal application is intended to exert predominantly systemic effects, with skin only a vehicle for administration. This form of application allows slow and gradual release of medication into the bloodstream with relatively constant blood levels. Topical administration exerts mainly peripheral effects at the site of application. </p> </section> <section id="CD010967-sec-0044"> <h4 class="title">Ongoing studies</h4> <p>We found one registered, randomised study on the efficacy and safety of TC 1% gel compared with placebo or ketamine (<a href="./references#CD010967-bbs2-0011" title="NCT00661063.Diabetic neuropathy topical treatment. www.clinicaltrials.gov/ct2/show/NCT00661063 (first received 18 April 2008). ">NCT00661063</a>). Planned study duration was 12 weeks. The study was to start in 2008, but we have found no study results. We tried to contact study authors by phone and email (as provided in the study description on ClinicalTrials.gov), but have received no response. For details, see <a href="./references#CD010967-sec-0125" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD010967-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>We used Cochrane's domain‐based evaluation table, which is provided in Review Manager Web (<a href="./references#CD010967-bbs2-0078" title="Review Manager Web (RevMan Web).Version 3.0.1. The Cochrane Collaboration, 2020. Available at revman.cochrane.org.">RevMan Web 2020</a>), to assess the validity and quality of included trials. Details of the assessment are specified in the <a href="./references#CD010967-sec-0123" title="">Characteristics of included studies</a> table, and summaries of assessments are provided in <a href="#CD010967-fig-0002">Figure 2</a> and <a href="#CD010967-fig-0003">Figure 3</a>. None of the studies was at low risk of bias in all domains. We judged one study as having high risk of bias for blinding of participants and personnel (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>); two studies as having high risk of bias for incomplete outcome data (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>); one study as having high risk of bias for selective reporting (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>); and three studies as having high risk of bias for funding bias (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). We assessed all of the included studies as having unclear risk of bias for allocation concealment, blinding of outcome assessment, and study size. Two studies were at unclear risk of bias for random sequence generation and blinding of participants and personnel (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). </p> <div class="figure" id="CD010967-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010967-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010967-sec-0046"> <h4 class="title">Allocation</h4> <section id="CD010967-sec-0047"> <h5 class="title">Random sequence generation</h5> <p>We assessed two studies as at low risk of bias for random sequence generation (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>). We judged two studies as having unclear risk of bias for this domain, as the study authors only stated that the study was randomised, providing no information on method of randomisation; however, there was also no information provided suggesting that randomisation was done improperly (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). </p> </section> <section id="CD010967-sec-0048"> <h5 class="title">Allocation concealment</h5> <p>We assessed all studies as at unclear risk of bias for allocation concealment. The study authors did not provide information on allocation concealment, although there was also no information provided suggesting that allocation concealment was absent or done improperly.  </p> </section> </section> <section id="CD010967-sec-0049"> <h4 class="title">Blinding</h4> <section id="CD010967-sec-0050"> <h5 class="title">Blinding of participants and personnel</h5> <p>We assessed one study as at low risk of bias for blinding of participants and personnel (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>). The study authors stated that the placebo formulation was identical in appearance, consistency, packaging, and labelling as the intervention drug. We judged two studies as having unclear risk of bias for this domain, as study authors provided no information on blinding method, although there was also no information provided suggesting that blinding was done improperly or was not performed (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). We judged one study as having high risk of bias for this domain, as even though the drugs were packed in no‐label laminated tubes, clonidine was provided in gel form and capsaicin in cream form (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>). </p> </section> <section id="CD010967-sec-0051"> <h5 class="title">Blinding of outcome assessment</h5> <p>We assessed all studies as at unclear risk of bias for blinding of outcome assessment. Study authors did not provide information on whether outcome assessment was blinded or not, although there was also no information provided suggesting that blinding of outcome assessment was done improperly or was not performed. </p> </section> </section> <section id="CD010967-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed two studies as having low risk of attrition bias, as baseline observation carried forward or multiple imputations by the regression method was used as an imputation method, and clear information about the number of participants lost from observation was provided (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>). We judged <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> as having high risk of attrition bias because the number of participants randomly assigned was not equal to the number described in the demographics table (one participant is missing). Some results are missing, and researchers provide no information about how they dealt with missing data in this study. We judged <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a> as having high risk of attrition bias because 13 participants in the TC group and 16 participants in the placebo group did not complete the study, and no information about how missing data were dealt with is provided by study authors. </p> </section> <section id="CD010967-sec-0053"> <h4 class="title">Selective reporting</h4> <p>Study protocols were available for three studies, which we assessed as having low risk of reporting bias. Results for all outcomes listed in the protocols were reported and presented clearly. The results were also consistent with the methods section of the studies (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). We judged <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> as having high risk of reporting bias because a study protocol was not available, and presentation of results was unclear. </p> </section> <section id="CD010967-sec-0054"> <h4 class="title">Other potential sources of bias</h4> <section id="CD010967-sec-0055"> <h5 class="title">Study size</h5> <p>All studies included between 50 and 199 participants per treatment arm, and were therefore assessed as at unclear risk of bias for study size. </p> </section> <section id="CD010967-sec-0056"> <h5 class="title">Funding bias</h5> <p>We assessed one study as at low risk of funding bias, because the study was supported by a grant from Hamedan University of Medical Sciences. Three studies were supported by industry funding and were judged as at high risk of funding bias. A biotechnology company, Arcion Therapeutics, supported two of these studies (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>), and a pharmaceutical company, BioDelivery Sciences International, supported one study (<a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>).  </p> </section> </section> </section> <section id="CD010967-sec-0057"> <h3 class="title" id="CD010967-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD010967-tbl-0001"><b>Summary of findings 1</b> Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</a>; <a href="./full#CD010967-tbl-0002"><b>Summary of findings 2</b> Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</a> </p> <p>See <a href="./full#CD010967-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD010967-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD010967-sec-0058"> <h4 class="title">Topical clonidine (TC) versus placebo</h4> <p>Three studies (604 participants) evaluated this comparison (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>). </p> <section id="CD010967-sec-0059"> <h5 class="title">Primary outcome measures</h5> <section id="CD010967-sec-0060"> <h6 class="title">Participant‐reported pain relief of 50% or greater during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported on participant‐reported pain relief of 50% or greater during longest follow‐up period (12 weeks). Thirty‐five per cent of participants in the TC group and 29% of participants in the placebo group achieved this outcome. There was no evidence of a difference between groups (risk ratio (RR) 1.21, 95% confidence interval (CI) 0.78 to 1.86). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0061"> <h6 class="title">Participant‐reported pain relief of 30% or greater during longest follow‐up period</h6> <p>Two studies (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 344 participants) in adults with PDN reported on participant‐reported pain relief of 30% or greater during longest follow‐up period (8 to 12 weeks). Meta‐analysis of the results shows that more participants in the TC group experienced at least 30% pain reduction (48% of participants) compared with those given placebo (36% of participants) during an 8‐ to 12‐week treatment period (RR 1.35, 95% CI 1.03 to 1.77) (<a href="./references#CD010967-fig-0006" title="">Analysis 1.1</a>; <a href="#CD010967-fig-0004">Figure 4</a>). The number needed to treat for an additional beneficial outcome (NNTB) to achieve this endpoint was 8.33 (95% CI 4.3 to 50). We judged the certainty of evidence to be very low for this outcome, downgraded for serious study limitations due to risk of bias, imprecision (optimal information size not met), and publication bias (fewer than 200 participants in unpublished null effect studies required to make the result clinically irrelevant). </p> <div class="figure" id="CD010967-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.1 Pain relief ≥ 30%." data-id="CD010967-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.1 Pain relief ≥ 30%. </p> </div> </div> </div> </section> <section id="CD010967-sec-0062"> <h6 class="title">Much or very much improved on Patient Global Impression of Change scale (PGIC) during longest follow‐up period </h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported an outcome defined as much or very much improved on PGIC during longest follow‐up period (12 weeks). There was no evidence of a difference between groups (RR 1.06, 95% CI 0.76 to 1.49). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met).  </p> </section> <section id="CD010967-sec-0063"> <h6 class="title">Very much improved on PGIC during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported an outcome defined as very much improved on PGIC during longest follow‐up period (12 weeks). There was no evidence of a difference between groups (RR 1.82, 95% CI 0.89 to 3.72). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> </section> <section id="CD010967-sec-0064"> <h5 class="title">Secondary outcome measures</h5> <section id="CD010967-sec-0065"> <h6 class="title">Withdrawals due to adverse events during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported on withdrawals due to adverse events during longest follow‐up period (12 weeks). There was no evidence of a difference between groups (RR 0.34, 95% CI 0.04 to 3.18). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0066"> <h6 class="title">Participants experiencing at least one adverse event during longest follow‐up period</h6> <p>Two studies (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 344 participants) in adults with PDN reported on participants experiencing at least one adverse event during longest follow‐up period (12 weeks). Meta‐analysis of the results showed no evidence of a difference between groups (11.7% versus 12.9% in TC and placebo groups, respectively; RR 0.65, 95% CI 0.14 to 3.05; <a href="./references#CD010967-fig-0007" title="">Analysis 1.2</a>; <a href="#CD010967-fig-0005">Figure 5</a>). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> <div class="figure" id="CD010967-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.2 Participants with ≥ 1 adverse event." data-id="CD010967-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.2 Participants with ≥ 1 adverse event. </p> </div> </div> </div> </section> <section id="CD010967-sec-0067"> <h6 class="title">Withdrawals due to lack of efficacy during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported on withdrawals due to lack of efficacy during longest follow‐up period (12 weeks). There was no evidence of a difference between groups (RR 1.01, 95% CI 0.06 to 15.92). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0068"> <h6 class="title">Participants experiencing at least one serious adverse event during longest follow‐up period </h6> <p>Two studies (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>; 439 participants) in adults with PDN reported on participants experiencing at least one serious adverse event during longest follow‐up period. Meta‐analysis of the results shows no evidence of a difference between TC and placebo for this outcome (RR 1.71, 95% CI 0.70 to 4.22; <a href="./references#CD010967-fig-0008" title="">Analysis 1.3</a>). We judged the certainty of evidence to be moderate for this outcome, downgraded for serious study limitations due to risk of bias. </p> <p><a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> reported one severe adverse event in the placebo group. However, the study did not specify the adverse event and whether it met the criteria for serious adverse events as indicated in this review, thus we did not include the study in the meta‐analysis. </p> </section> <section id="CD010967-sec-0069"> <h6 class="title">Specific adverse events, in particular somnolence and dizziness during longest follow‐up period </h6> <p>Two studies (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 344 participants) in adults with PDN reported on participants with specific adverse events. <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a> reported the same number of participants with adverse events associated with the nervous system (two participants per group), which included burning sensation, dizziness, and headache. <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> described 11 adverse events associated with the nervous system in the TC group, and eight in the placebo group. The study authors did not specify these adverse events. Meta‐analysis of the results shows no evidence of a difference between TC and placebo for this outcome (RR 0.77, 95% CI 0.35 to 1.68 <a href="./references#CD010967-fig-0009" title="">Analysis 1.4</a>). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0070"> <h6 class="title">Any pain‐related outcome indicating some improvement during longest follow‐up period (including physical and emotional functioning) </h6> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported on pain relief quantified in scales assessing quality of life. Study investigators did not report evidence of a difference between groups for the Brief Pain Inventory, Chronic Pain Sleep Inventory, or Hospital Anxiety and Depression Scale. We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0071"> <h6 class="title">Skin biopsy results </h6> <p>None of the included studies assessed skin biopsy results.</p> </section> <section id="CD010967-sec-0072"> <h6 class="title">Change in average pain intensity during longest follow‐up period</h6> <p>Pain intensity was reported by participants in their diaries using the NRS.</p> <p>One study (<a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; 179 participants) in adults with PDN reported on change in average pain intensity during longest follow‐up period. There was evidence of a difference between groups (2.3‐point reduction in TC group compared with a 1.7‐point reduction in placebo group; mean difference 0.6; P = 0.07). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met).  </p> </section> </section> </section> <section id="CD010967-sec-0073"> <h4 class="title">TC versus active comparator</h4> <p>One study (139 participants) evaluated topical clonidine versus topical capsaicin (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>). </p> <section id="CD010967-sec-0074"> <h5 class="title">Primary outcome measures</h5> <section id="CD010967-sec-0075"> <h6 class="title">Participant‐reported pain relief of 50% or greater during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>; 139 participants) in adults with PDN reported on participant‐reported pain relief of 50% or greater during longest follow‐up period (12 weeks). This outcome was achieved by 57.1% of participants in the TC group and 40.6% of participants in the topical capsaicin group. There was no evidence of a difference between groups (RR 1.41, 95% CI 0.99 to 2.0). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0076"> <h6 class="title">Participant‐reported pain relief of 30% or greater during longest follow‐up period</h6> <p>The included study did not report on participant‐reported pain relief of 30% or greater during longest follow‐up period. </p> </section> <section id="CD010967-sec-0077"> <h6 class="title">Much or very much improved on PGIC during longest follow‐up period</h6> <p>The included study did not report on much or very much improved on PGIC during longest follow‐up period. </p> </section> <section id="CD010967-sec-0078"> <h6 class="title">Very much improved on PGIC during longest follow‐up period</h6> <p>The included study did not report on very much improved on PGIC during longest follow‐up period. </p> </section> </section> <section id="CD010967-sec-0079"> <h5 class="title">Secondary outcome measures</h5> <section id="CD010967-sec-0080"> <h6 class="title">Withdrawals due to adverse events during longest follow‐up period</h6> <p>The included study did not report on withdrawals due to adverse events during longest follow‐up period. </p> </section> <section id="CD010967-sec-0081"> <h6 class="title">Participants experiencing at least one adverse event during longest follow‐up period</h6> <p>The included study did not report on participants experiencing at least one adverse event during longest follow‐up period. </p> </section> <section id="CD010967-sec-0082"> <h6 class="title">Withdrawals due to lack of efficacy during longest follow‐up period</h6> <p>The included study did not report on withdrawals due to lack of efficacy during longest follow‐up period. </p> </section> <section id="CD010967-sec-0083"> <h6 class="title">Participants experiencing at least one serious adverse event during longest follow‐up period </h6> <p>The included study did not report on participants experiencing at least one serious adverse event during longest follow‐up period. </p> </section> <section id="CD010967-sec-0084"> <h6 class="title">Specific adverse events, in particular somnolence and dizziness during longest follow‐up period </h6> <p>One study (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>; 139 participants) in adults with PDN reported on dermatologic complications. More participants (58%) in the topical capsaicin group had dermatologic complications compared with the TC group (5.7%) (RR 0.10, 95% CI 0.04 to 0.26). We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met). </p> </section> <section id="CD010967-sec-0085"> <h6 class="title">Any pain‐related outcome indicating some improvement during longest follow‐up period (including physical and emotional functioning) </h6> <p>The included study did not report on any pain‐related outcome indicating some improvement during longest follow‐up period (including physical and emotional functioning). </p> </section> <section id="CD010967-sec-0086"> <h6 class="title">Skin biopsy results </h6> <p>The included study did not report on skin biopsy results.</p> </section> <section id="CD010967-sec-0087"> <h6 class="title">Change in average pain intensity during longest follow‐up period</h6> <p>One study (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>; 139 participants) in adults with PDN reported on change in average pain intensity during longest follow‐up period. Participants reported the reduction in the median pain score from baseline, as assessed by the VAS during follow‐up visits. Study authors reported no evidence of a difference between the TC and topical capsaicin groups. We judged the certainty of evidence to be low for this outcome, downgraded for serious study limitations due to risk of bias, and imprecision (optimal information size not met).  </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010967-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010967-sec-0088"></div> <section id="CD010967-sec-0089"> <h3 class="title" id="CD010967-sec-0089">Summary of main results</h3> <p>This updated review includes four trials with a total of 743 participants; two of these studies were newly included in this update, and the conclusions have not changed. All studies were conducted in adults with painful diabetic neuropathy (PDN). Studies lasted 8 or 12 weeks and compared topical clonidine (TC) versus placebo (<a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>; <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>; <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>), or TC versus topical capsaicin (<a href="./references#CD010967-bbs2-0003" title="KianiJ , SajediF , NasrollahiSA , Esna-AshariF .A randomized clinical trial of efficacy and safety of the topical clonidine and capsaicin in the treatment of painful diabetic neuropathy. Journal of Research in Medical Sciences2015;20(4):359-63. ">Kiani 2015</a>). 0.1% or 0.2% TC in gel form was applied to the painful area two to three times daily. </p> <p>There was no evidence of a difference in number of participants with participant‐reported pain relief of 50% or greater during longest follow‐up period; however, the number of participants with participant‐reported pain relief of 30% or greater during longest follow‐up period (8 to 12 weeks) was higher in the TC group compared with the placebo group. Nevertheless, the number needed to treat for an additional beneficial outcome (NNTB) for this outcome was relatively high. Also, one study (179 participants) showed no difference in improvement classified by participants as much or very much improved on Patient Global Impression of Change scale (PGIC) or very much improved on PGIC during longest follow‐up period (12 weeks), based on low certainty evidence. Furthermore, we observed no evidence of a difference in rate of withdrawals due to adverse events, rate of withdrawals due to lack of efficacy, and number of participants experiencing at least one serious adverse event during longest follow‐up period (12 weeks), based on low certainty evidence. </p> <p>Based on low certainty evidence from one study (139 participants), there was no evidence of a difference between TC and topical capsaicin in participant‐reported pain relief of 50% or greater or change in average pain intensity during longest follow‐up period (12 weeks); however, a lower rate of dermatologic complications was observed in the TC group. </p> </section> <section id="CD010967-sec-0090"> <h3 class="title" id="CD010967-sec-0090">Overall completeness and applicability of evidence</h3> <p>One of the crucial limitations of the available evidence is that all of the studies included in the review were performed in adults with PDN. We found no studies in other neuropathic pain conditions such as trigeminal neuralgia, postherpetic neuralgia, phantom limb pain, and others, hence the evidence does not fully address the review question, and conclusions cannot be generalised to the whole population of adults with neuropathic pain.  </p> <p>It should be noted that in <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a>, the study exclusion criteria were very strict; for example, patients with symptomatic or severe coronary insufficiency, clinically significant cardiac conduction disturbances, myocardial infarction (within last 12 months), or moderate to severe cerebrovascular disease were excluded. Yet, many people with diabetes have these cardiovascular diseases. It is therefore uncertain if the study findings are valid for many adults with painful diabetic peripheral neuropathy in clinical practice. </p> <p>Moreover, in <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a>, participants experienced stimulation with 0.1% capsaicin during the screening phase. Even though topical capsaicin in a concentration of 8% may produce long‐lasting pain relief (<a href="./references#CD010967-bbs2-0026" title="DerryS , Sven-RiceA , ColeP , TanT , MooreRA .Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews2013, Issue 2. Art. No: CD007393. [DOI: 10.1002/14651858.CD007393.pub3]">Derry 2013</a>), we believe that 0.1% capsaicin should not influence response to clonidine; however, such a situation cannot be ruled out completely. Even though the study authors claim better results amongst capsaicin responders, there is no clear evidence of a difference between TC and placebo in this subgroup of participants in change in PGIC, and results for at least 50% and 30% pain relief are not presented. </p> </section> <section id="CD010967-sec-0091"> <h3 class="title" id="CD010967-sec-0091">Quality of the evidence</h3> <p>Overall, we judged the evidence to be of moderate to very low certainty. </p> <p>There were three potential problems for which we downgraded the certainty of the evidence, as follows. </p> <p> <ul id="CD010967-list-0019"> <li> <p>Study limitations. The studies were at unclear or high risk for most risk of bias domains: all were at unclear risk of bias for allocation concealment and blinding of outcome assessment; one study was at high risk of bias for blinding of participants and personnel; two studies were at high risk of attrition bias; and three studies were at high risk of bias due to notable funding concerns.  </p> </li> <li> <p>Imprecision of results. For all outcomes except participants experiencing at least one serious adverse event during longest follow‐up period, the optimal information size was not met. Most of the results, excluding participant‐reported pain relief of 30% or greater during longest follow‐up period, had wide confidence intervals crossing the line of no effect and including both benefit and harm. </p> </li> <li> <p>High probability of publication bias. We assessed publication bias using a method designed to detect the quantity of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean an NNTB ≥ 10 in this condition; <a href="./references#CD010967-bbs2-0062" title="MooreRA , BardenJ , DerryS , McQuayHJ .Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ 978–0–931092–69–5]">Moore 2008</a>). In our review, fewer than 200 participants in unpublished null effect studies would rise NNTB to over 10, which indicates a high probability of publication bias. </p> </li> </ul> </p> </section> <section id="CD010967-sec-0092"> <h3 class="title" id="CD010967-sec-0092">Potential biases in the review process</h3> <p>We followed the guidelines provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010967-bbs2-0042" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s).Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021a</a>), and took measures to reduce bias in the review process. We used a comprehensive search strategy based on previous Cochrane Reviews for randomised controlled trials on neuropathic pain. We did not restrict our search to topical application of the drug, so that we could identify all relevant studies. Additionally, we searched reference lists of potentially relevant studies and reviews and trial registries and contacted experts in the field. Two review authors independently read abstracts identified by the search. The probability that any important studies were omitted in the search process is low, as is the possibility of bias in this review process. </p> <p>Two review authors worked independently to assess bias and extract data from the included studies, consulting a third review author when necessary. We contacted study authors whenever we encountered missing information; however, this information was only obtainable in the case of <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a>, and in many cases this lack of information precluded comprehensive data extraction or bias assessment. Moreover, it should be noted that <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> was based on the published abstract and on unpublished data provided by study authors, and the assessment of <a href="./references#CD010967-bbs2-0004" title="NCT02068027.Safety and efficacy study of clonidine hydrochloride topical gel, 0.1%, in the treatment of pain associated with diabetic neuropathy. www.clinicaltrials.gov/ct2/show/NCT02068027 (first received 20 February 2014). ">NCT02068027</a> was based only on unpublished data, so the studies are at high risk of reporting bias.  </p> <p>Whilst we tried to minimise the influence of publication bias in the review process, the review may nevertheless be subject to it. There is one study with no published results (<a href="./references#CD010967-bbs2-0011" title="NCT00661063.Diabetic neuropathy topical treatment. www.clinicaltrials.gov/ct2/show/NCT00661063 (first received 18 April 2008). ">NCT00661063</a>). It is possible that this study has negative results and might, if included into the analysis, have resulted in an NNTB ≥ 10, which would make the results clinically irrelevant.  </p> <p>Moreover, it should be noted that long‐term studies, which are relevant to chronic pain conditions, are missing. This could have serious impact on the conclusions drawn from this review, as long‐term studies might have not confirmed our findings. </p> </section> <section id="CD010967-sec-0093"> <h3 class="title" id="CD010967-sec-0093">Agreements and disagreements with other studies or reviews</h3> <p>In 2019, Yang and colleagues published a review summarising the evidence on the available agents for topical use in people with PDN (without age restriction), including lidocaine plasters or patches, capsaicin cream, gel or patches, amitriptyline cream, clonidine gel, ketamine cream, and other agents (<a href="./references#CD010967-bbs2-0095" title="YangX , FangP , XiangD , YangY .Topical treatments for diabetic neuropathic pain (Review). Experimental and Therapeutic Medicine2019;17(3):1963-76.">Yang 2019</a>). For topical clonidine (TC), the review included <a href="./references#CD010967-bbs2-0001" title="CampbellC , CampbellJ , SchmidtW , BradyK , StouchB .Topical clonidine gel reduces pain caused by diabetic neuropathy: results of a multicenter, placebo-controlled clinical trial. Journal of Pain2009;4:S55. ">Campbell 2009</a> and <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a> studies and referred to a previous version of our review (<a href="./references#CD010967-bbs2-0097" title="WrzosekA , WoronJ , DobrogowskiJ , Jakowicka-WordliczekJ , WordliczekJ .Topical clonidine for neuropathic pain. Cochrane Database of Systematic Reviews2015, Issue 8. Art. No: CD010967. [DOI: 10.1002/14651858.CD010967.pub2]">Wrzosek 2015</a>). The conclusions of that review are consistent with the results of our work. </p> <p>The Neuropathic Pain Special Interest Group conducted a comprehensive systematic review with meta‐analysis published in 2015 focusing on pharmacotherapy for neuropathic pain in patients of any age (<a href="./references#CD010967-bbs2-0033" title="FinnerupNB , AttalN , HaroutounianS , McNicolE , BaronR , DworkinRH , et al.Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurology2015;14(2):162-73. [PMID: 25575710]">Finnerup 2015</a>). For TC, the review included the <a href="./references#CD010967-bbs2-0002" title="CampbellCM , KipnesMS , StouchBC , BradyKL , KellyM , SchmidtWK , et al.Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain2012;153(9):1815-23. ">Campbell 2012</a> study, but not the other studies included in our review. Additionally, Finnerup and colleagues included two studies that were excluded from our review due to transdermal, not topical, drug delivery (<a href="./references#CD010967-bbs2-0006" title="Byas-SmithMG , MaxMB , MuirJ , KingmanACN .Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage 'enriched enrollment' design. Pain1995;60(3):267-74. ">Byas‐Smith 1995</a>; <a href="./references#CD010967-bbs2-0010" title="ZeiglerD , LynchSA , MuirJ , BenjaminJ , MaxMBCN .Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain1992;48(3):403-8. ">Zeigler 1992</a>). Both of these studies assessed the efficacy and safety of TC in PDN. The review authors state that GRADE recommendations for TC for neuropathic pain are inconclusive because of discrepant findings; however, they based this conclusion on evidence from different clinical trials than those included in our review.  </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010967-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD010967-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010967-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010967-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.1 Pain relief ≥ 30%." data-id="CD010967-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.1 Pain relief ≥ 30%. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.2 Participants with ≥ 1 adverse event." data-id="CD010967-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topical clonidine versus placebo in painful diabetic neuropathy, outcome: 1.2 Participants with ≥ 1 adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 1: Participant‐reported pain relief of 30% or greater during longest follow‐up period" data-id="CD010967-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 1: Participant‐reported pain relief of 30% or greater during longest follow‐up period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#CD010967-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 2: Participants experiencing at least 1 adverse event during longest follow‐up period" data-id="CD010967-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 2: Participants experiencing at least 1 adverse event during longest follow‐up period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#CD010967-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 3: Participants experiencing at least 1 serious adverse event during longest follow‐up period" data-id="CD010967-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 3: Participants experiencing at least 1 serious adverse event during longest follow‐up period </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#CD010967-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010967-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/urn:x-wiley:14651858:media:CD010967:CD010967-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 4: Participants experiencing at least 1 adverse event associated with the nervous system" data-id="CD010967-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_t/tCD010967-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Topical clonidine versus placebo in painful diabetic neuropathy, Outcome 4: Participants experiencing at least 1 adverse event associated with the nervous system </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#CD010967-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/media/CDSR/CD010967/image_n/nCD010967-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010967-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Participants or population:</b> adults with painful diabetic neuropathy </p> <p><b>Settings:</b> primary care, outpatient </p> <p><b>Intervention:</b> 0.1% or 0.2% clonidine gel applied to both feet 2 to 3 times daily </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>NNTB<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>29 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>35 per 100<br/>(23 to 54) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.21 (0.78 to 1.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater during longest follow‐up period</p> <p>(8 to 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>36 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>49 per 100</p> <p>(37 to 64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.35 (1.03 to 1.77)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (4.3 to 50.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Evidence of a difference present</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Much or very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>42 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 100</p> <p>(32 to 63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.06 (0.76 to 1.49)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 100<br/>(10 to 41) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.82 (0.89 to 3.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> <p>(0 to 10)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.34 (0.04 to 3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least 1<br/>adverse event during longest follow‐up period </p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>13 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>10 per 100</p> <p>(6 to 19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.65 (0.14 to 3.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>344</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to lack of efficacy</p> <p>(12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 per 100<br/>(0 to 16) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01 (0.06 to 15.92)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*Mean baseline risk was chosen to determine the <b>assumed risk</b> in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>PGIC:</b> Patient Global Impression of Change scale; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants).<br/><sup>b</sup>Downgraded one level for serious study limitations (the studies were judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment); one level for imprecision of results (optimal information size not met: fewer than 400 participants); and one level for publication bias (fewer than 200 participants in unpublished null effect studies required to make the result clinically irrelevant).<br/><sup>c</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants, wide confidence intervals, small number of events).<br/><sup>d</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of funding bias and unclear risk of bias for allocation concealment and blinding of outcome assessment) and one level for imprecision of results (optimal information size not met: fewer than 400 participants, wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Topical clonidine (TC) compared with placebo for chronic neuropathic pain in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD010967-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Participants or population:</b> adults with painful diabetic neuropathy </p> <p><b>Settings:</b> tertiary care setting  </p> <p><b>Intervention:</b> 0.1% clonidine gel self administered 3 times daily on both feet </p> <p><b>Comparison:</b> 0.75% capsaicin cream self administered 3 times daily on both feet </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect</b> <br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p>NNTB<br/><b>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants</b> <br/><b>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of evidence</b> <br/><b>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Topical capsaicin</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>TC</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 50% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>57 per 100</p> <p>(41 to 82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.41</p> <p>(0.99 to 2.0)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not calculated</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139 <br/>(1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported pain relief of 30% or greater during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Much or very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Very much improved on PGIC during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events during longest follow‐up period</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing at least 1<br/>adverse event during longest follow‐up period </p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawal due to lack of efficacy</p> <p>(12 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="7" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*Mean baseline risk was chosen to determine the <b>assumed risk</b> in the control group. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>NNTB:</b> number needed to treat for an additional beneficial outcome; <b>PGIC:</b> Patient Global Impression of Change scale; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different.<br/><b>Low certainty</b> : our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty</b>: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for serious study limitations (the study was judged as at high risk of bias for blinding of participants and personnel and unclear risk of bias for allocation concealment, blinding of outcome assessment, and study size domains) and one level for imprecision of results (optimal information size not met: more than 50 and fewer than 199 participants per treatment arm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Topical clonidine (TC) compared with active comparator for chronic neuropathic pain in adults</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/full#CD010967-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010967-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical clonidine versus placebo in painful diabetic neuropathy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Participant‐reported pain relief of 30% or greater during longest follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [1.03, 1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Participants experiencing at least 1 adverse event during longest follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.14, 3.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Participants experiencing at least 1 serious adverse event during longest follow‐up period <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>439</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [0.70, 4.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Participants experiencing at least 1 adverse event associated with the nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.35, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topical clonidine versus placebo in painful diabetic neuropathy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010967.pub3/references#CD010967-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010967.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010967-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010967-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010967-note-0012">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010967-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD010967-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD010967-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD010967-note-0011">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD010967-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010967-note-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD010967-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010967\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010967\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010967\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010967\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010967\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010967.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010967.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010967.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010967.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010967.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725145103"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010967.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725145107"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010967.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7411dcd71be5',t:'MTc0MDcyNTE0NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 